ALGS News & Events

Aligos Therapeutics announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company's stock to newly hired employees on January 29, 2026, in connection with the commencement of employment.

Hardean Achneck, MD resigned from his position as Executive Vice President, Chief Medical Officer.

Aligos Therapeutics announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus, HBV, infection. The first protocol defined interim analysis includes approximately 60% HBeAg- participants that complete 12 weeks of the treatment period. This enrollment milestone occurred in Q4 2025. In addition, the planned enrollment of this cohort of 60 HBeAg- participants completed in January 2026. The first interim analysis is expected to occur in the first half of 2026. A second protocol defined interim analysis is planned when approximately 50% HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026. This interim analysis is expected to occur in the second half of 2026.